ANI Pharmaceuticals (ANIP) News Today

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $57.19, for a total transaction of $14,297.50. Following the transaction, the vice president now owns 56,488 shares in the company, valued at approximately $3,230,548.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and fiv

Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $68.00 target price on the stock.

Millennium Management LLC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1,005.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 230,079 shares of the specialty pharmaceutical company's stock after acquiring an a

Algert Global LLC lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 64.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,951 shares of the specialty pharmaceutical company's stock after

Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 630,226 shares of the specialty pharmaceutical company's stock after buying an addit

Maverick Capital Ltd. grew its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 302.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 18,536 shares of the specialty pharmaceutical company's stock after acquiring an additiona

American Century Companies Inc. boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 99.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 99,831 shares of the specialty pharmaceutic

Renaissance Technologies LLC increased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 15.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 156,802 shares of the specialty p

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Capital One Financial raised their Q3 2024 EPS estimates for shares of ANI Pharmaceuticals in a note issued to investors on Thursday, September 19th. Capital One Financial analyst T. Chiang now forecasts that the specialty pharmaceutical com

Rubric Capital Management LP lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 37.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 603,800 shares of the specialt

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2024 earnings estimates for ANI Pharmaceuticals in a report issued on Tuesday, September 17th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company wil

Raymond James lifted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a report on Wednesday.

ANI Pharmaceuticals (NASDAQ:ANIP) Shares Up 5.3%

HC Wainwright reaffirmed a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,420,000 shares, an increase of 44.9% from the August 15th total of 1,670,000 shares. Based on an average daily volume of 299,400 shares, the short-interest ratio is presently 8.1 days.

Natixis Advisors LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,639 shares of the specialty pharmac

ANI Pharmaceuticals (NASDAQ:ANIP) Sees Unusually-High Trading Volume

ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Down to $55.48

Truist Financial reaffirmed a "hold" rating and set a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday.

Bank of New York Mellon Corp boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 10.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,156 shares of the specialty

StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday.

Hussman Strategic Advisors Inc. raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 33.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,000 shares of the specialty pha

StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 1,670,000 shares, a growth of 439.8% from the July 31st total of 309,400 shares. Based on an average trading volume of 247,300 shares, the days-to-cover ratio is presently 6.8 days.